DiabetOmics is a medical devices company based in India. They offer the Lumella® Test, a point-of-care blood test that helps in the early detection of preeclampsia during pregnancy. The Lumella® test estimates the concentration of Glycosylated Fibronectin, a pregnancy-specific biomarker, to assess the risk of preeclampsia. This test can be performed with a simple finger stick in a physician's office during the first, second, or third trimesters of pregnancy. DiabetOmics focuses on providing innovative solutions for assessing and managing preeclampsia risk, aiming to improve maternal and fetal outcomes.